About Us

Built by scientists. Driven by impact.

Deep expertise in biomedical engineering, medical device commercialization, biosensing, and clinical AI — focused on a single mission.

Our Mission

Enabling earlier detection of acute kidney injury to improve patient outcomes, reduce preventable costs, and transform how hospitals manage high-risk patients.

We believe that the future of kidney care begins with better monitoring — shifting the paradigm from reactive treatment to proactive, data-driven intervention. RenalSignal is building the clinical intelligence layer that makes this possible.

Leadership

The founding team

Scientists and engineers translating breakthrough research into clinical reality.

Nettie Brown, PhD

Nettie Brown, PhD

Co-Founder & CEO

Biomedical Engineer (Georgia Tech & Emory) with medical device translation and commercialization experience. Founding technical lead at Mobius Biotech (3D-printed nasal scaffold), leading bench-to-clinical development, FDA engagement, and NSF I-Corps customer discovery. Now Founder-in-Residence at TMC Innovation Biodesign, developing technologies for early detection of acute kidney injury.

Khashayar Farzanian, PhD

Khashayar (Kash) Farzanian, PhD

Co-Founder & CTO

Engineer (University of Miami) with 5 years postdoctoral training spanning Yale cardiovascular mechanobiology and molecular biophysics. Led business development and commercialization strategy at Yale spinout AtlasXomics (spatial epigenomics). Now Founder-in-Residence at TMC Innovation Biodesign, translating biosensing + serial physiological data + AI into earlier AKI detection.

Born at TMC Innovation Biodesign — where clinical need meets engineering innovation.

RenalSignal emerged from the TMC Innovation Biodesign program at the Texas Medical Center — the world's largest medical complex — where our founders identified the urgent, unmet need for earlier AKI detection through deep clinical immersion and customer discovery.

Get In Touch

Interested in learning more or partnering?

We're actively speaking with health systems, investors, and potential collaborators. Reach out and we'll be in touch.

Thank you!

We'll be in touch soon.